Prelude Therapeutics Inc
$ 3.94
2.60%
09 Jun - close price
- Market Cap 303,449,000 USD
- Current Price $ 3.94
- High / Low $ 4.04 / 3.76
- Stock P/E N/A
- Book Value 0.96
- EPS -1.00
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.95 %
- 52 Week High 5.54
- 52 Week Low 0.75
About
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Analyst Target Price
$8.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-10 | 2025-11-12 | 2025-08-14 | 2025-05-06 | 2025-03-10 | 2024-11-06 | 2024-08-12 | 2024-05-07 | 2024-02-15 | 2023-11-01 | 2023-08-03 |
| Reported EPS | -0.13 | -0.2 | -0.26 | -0.41 | -0.42 | -0.37 | -0.43 | -0.46 | -0.42 | -0.46 | -0.45 | -0.54 |
| Estimated EPS | -0.2667 | -0.13 | -0.3697 | -0.48 | -0.48 | -0.4673 | -0.47 | -0.43 | -0.48 | -0.49 | -0.58 | -0.63 |
| Surprise | 0.1367 | -0.07 | 0.1097 | 0.07 | 0.06 | 0.0973 | 0.04 | -0.03 | 0.06 | 0.03 | 0.13 | 0.09 |
| Surprise Percentage | 51.2561% | -53.8462% | 29.6727% | 14.5833% | 12.5% | 20.8217% | 8.5106% | -6.9767% | 12.5% | 6.1224% | 22.4138% | 14.2857% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRLD
2026-06-09 13:10:11
Shareholders of Prelude Therapeutics Incorporated (PRLD) approved all proposals at their recent annual general meeting. This included the election of three directors, ratification of the company's auditor, and approval of executive compensation and its annual review. The final results will be officially filed with the SEC.
2026-05-20 11:12:46
This extensive analysis of Prelude Therapeutics (PRLD) covers its stock performance, financial health, and pipeline developments. The company, a clinical-stage precision oncology firm, is currently unprofitable but forecasts strong revenue growth. Recent updates include positive preclinical data for PRT13722 in breast cancer and FDA clearance for PRT12396 in myeloproliferative neoplasms, alongside ongoing shareholder dilution and share price volatility.
2026-05-17 10:40:45
Following its first-quarter results, Prelude Therapeutics (NASDAQ:PRLD) saw a dip in share price, but analysts quickly upgraded their estimates. Revenue forecasts for 2026 increased to US$27.3m, and the projected loss per share significantly narrowed to US$0.37. The company's price target also rose by 20% to US$8.25.
2026-05-15 09:40:27
Goldman Sachs has initiated coverage of Prelude Therapeutics Inc. (NASDAQ:PRLD) with an "Early-Stage Biotech" rating. The clinical-stage company, which develops cancer medicines, has seen its stock gain 377% over the past year and possesses over $10 billion in potential unadjusted peak sales for its lead metastatic breast cancer program. Upcoming milestones include an IND filing and Phase 1 initiation in mid-to-late 2026, with an opt-in decision for another key asset by February 2027.
2026-05-13 10:10:03
Prelude Therapeutics reported its first-quarter 2026 financial results, highlighting the advancement of PRT12396 into Phase 1 studies for polycythemia vera and myelofibrosis, and plans to file an IND for PRT13722, a KAT6A degrader, by mid-2026. The company appointed Charles Morris, M.D., as Chief Medical Officer and extended its cash runway into the second quarter of 2028 following a $90 million underwritten offering. Net loss decreased to $10.4 million from $32.1 million in the prior year, driven by lower R&D and G&A expenses.
2026-05-12 13:09:57
Prelude Therapeutics announced its Q1 2026 financial results, highlighting significant progress in its precision oncology pipeline, including the initiation of a Phase 1 study for PRT12396 and an upcoming IND filing for PRT13722. The company also reported a major decrease in net loss, with an extended cash runway into Q2 2028 following a $90 million offering. These developments position Prelude for several potential price-sensitive catalysts in the near future.
